Report
Christophe-Raphaël Ganet

bioMerieux : Q1 2025 revenue above expectations – guidance reiterated with a slightly higher FX impact than initially guided

Underlying
BioMerieux SA

Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Christophe-Raphaël Ganet

Other Reports on these Companies
Other Reports from Oddo BHF
Stefano Toffano ... (+2)
  • Stefano Toffano
  • Thomas Zlowodzki
Maissa Keskes ... (+3)
  • Maissa Keskes
  • Stephane Houri
  • Thomas Zlowodzki

ResearchPool Subscriptions

Get the most out of your insights

Get in touch